Detomax

Detomax is a relatively selective alpha2-adrenergic agonist indicated for

Sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. Administer Detomax by continuous infusion not to exceed 24 hours.

Sedation of non-intubated patients prior to and/or during surgical and other procedures.

Individualize and titrate Dexmeditomidine dosing to desired clinical effect.

Administer Dexmeditomidine using a controlled infusion device.

Dilute the 200 mcg/2 mL (100 mcg/mL) vial contents in 0.9% sodium chloride solution to achieve required concentration (4 mcg/mL) prior to administration.

The 200 mcg/50 mL single-use bottles do not require further dilution prior to administration.

For Adult Intensive Care Unit Sedation

: Generally initiate at one mcg/kg over 10 minutes,  followed by a maintenance infusion of 0.2 to 0.7 mcg/kg/hour.

For Adult Procedural Sedation

: Generally initiate at one mcg/kg over 10 minutes, followed by a maintenance infusion initiated at 0.6 mcg/kg/hour and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hour.

Alternative Doses

: Recommended for patients over 65 years of age and awake fiberoptic

intubation patients.

Dexmedetomidine is a specific and selective alpha-2 adrenoceptor agonist. By binding to the presynaptic alpha-2 adrenoceptors, it inhibits the release if norepinephrine, therefore, terminate the propagation of pain signals. Activation of the postsynaptic alpha-2 adrenoceptors inhibits the sympathetic activity decreases blood pressure and heart rate.

Body as a Whole

: Fever, hyperpyrexia, hypovolemia, light anesthesia, pain, rigors

Cardiovascular Disorders, General

: Blood pressure fluctuation, heart disorder, hypertension, hypotension, myocardial infarction

Central and Peripheral Nervous System Disorders

: Dizziness, headache, neuralgia, neuritis, speech disorder, convulsion

• Gastrointestinal System Disorders
• : Abdominal pain, diarrhea, vomiting, nausea
• Liver and Biliary System Disorders

: Increased gamma-glutamyl transpeptidase, hepatic function abnormal, hyperbilirubinemia

Metabolic and Nutritional Disorders

: Acidosis, respiratory acidosis, hyperkalemia, thirst, hypoglycemia

• Psychiatric Disorders
• : Agitation, confusion, delirium, hallucination, illusion
• Red Blood Cell Disorders
• : Anemia
• Renal Disorders
• : Blood urea nitrogen increased, oliguria
• Respiratory System Disorders
• : Hypoventilation, hypoxia, pulmonary congestion
• Skin Disorders
• : Increased sweating
• Vascular Disorders
• : Hemorrhage
• Vision Disorders

: Photopsia, abnormal vision.

Continuous monitoring is needed while patient receiving Detomax.

Pregnancy Category C.

Bradycardia, hypotension and cardiac arrest is observed.

Co-administration of Detomax with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.